The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients

This study investigates the relationship of circulating microRNA-30e and schizophrenia, and shows the relevance of the aberrant microRNA-30e expression in plasma with the variation disease status.

The plasma samples from 15 individuals with schizophrenia (with a diagnosis of ICD-10) and the equivalent healthy controls will be conducted with the quantification analysis of the microRNA-30e via real-time quantitative polymerase chain reaction(RT-PCR).

The 15 patients enrolled should be the first-episode and have not been treated, or were drug free 3 months recently at least.

This research measures the expression level of microRNA-30e in schizophrenia respectively before the beginning treatment with atypical psychotics or combined with MECT, after the 4-week treated , the 8-week treated compared with 15 healthy controls.

Inclusion Criteria:

• Persons should be diagnosed with schizophrenia according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)
• The first-onset or drug-free in the latest 3 months
• Between the ages of 17-40

Exclusion Criteria:

• Comorbid with other psychosis
• Have physical or neurological diseases such as traumatic brain injuries
• History of drug-abused or alcoholic
• Blood transfusion history in a month
• Been treated with Modified Electric Convulsive Therapy(MECT) in late 3 months